Branch duct type Intraductal papillary mucinous neoplasms
Conditions
Interventions
administration of sulindac (150mg twice daily)
placebo
Sponsors
Fourth Department of Internal Medicine, Sapporo medical university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. There is grape-like cystic dilatation of pancreatic branch duct. 2. Pancreatogram or duodenoscope revealed the existence of mucin, or the cystic lesion was pathologically proven IPMN. 3. Patients fully understand and are willing to give a written informed consent about participation.
Exclusion criteria
Exclusion criteria: 1. The lesion was histologically or cytologically proven malignant. 2. Imaging modality revealed suspicious findings of invasion derived from IPMN. 3. Imaging modality revealed coexistence of pancreatic ductal cancer. 4. Imaging modality revealed mural nodule, which is 10 mm or more. 5. Regular use of NSAIDs. 6. Allergy to NSAIDs. 7. Active peptic ulcer. 8. Severe hematological disturbance, liver damage, renal dysfunction or heart failure. 9. Past history of aspirin- or NSAIDs-induced asthma. 10. Creatinine >= 1.5 mg/dl. 11. Allergy to contrast medium. 12. Patient cannot have MRI because of implantation of metal or pacemaker. 13. Patients with lactation or pregnancy. 14. Patient with coinciding active malignancies. 15. Patient with active infection. 16. ECOG performance status is 3 or 4. 17. Patient with disturbance of consciousness (Japan coma scale >= I-1). 18. Patient who was considered ineligible based on decision of a reasonable investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change of branch duct diameter | — |
Countries
Japan
Contacts
Public ContactTsuyoshi Hayashi
Sapporo Medical University Fourth Department of Internal Medicine
Outcome results
None listed